MetaCap

enGene Therapeutics (ENGN) vs Sutro Biopharma (STRO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Sutro Biopharma (STRO) has outperformed enGene Therapeutics (ENGN) over the past year, gaining 2.4% versus a loss of 75.0%. Sutro Biopharma is the larger company by market cap ($142.8 million vs $116.6 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ENGN-75.00%STRO+2.38%
+410%+154%-103%
Nov 21, 20251 yearNov 20, 2026
ENGN-82.35%STRO-91.18%
+203%+47%-109%
Jan 31, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ENGN versus STRO key metrics
MetricENGNSTRO
Share price$1.74$8.60
Market cap$116.61M$142.77M
1-day change-1.14%-1.38%
YTD return-80.73%-25.67%
1-year return-75.00%+2.38%
5-year return—-94.68%
EPS (TTM)$-2.07$-12.42
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$102.48M
Revenue growth (YoY)—+65.18%
Net income (latest FY)$-117.30M$-191.09M
Operating margin—-154.53%
Net margin—-186.45%
52-week high$12.25$43.85
52-week low$1.40$7.15
Distance from 52-week high-85.80%-80.39%
Analyst consensusbuystrong_buy
Avg. price target upside+146.55%+419.65%
Average volume1.12M304.90K
Shares outstanding67.02M16.60M
Employees81129
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • STRO has outperformed ENGN by 77.4 percentage points over the past year.

About enGene Therapeutics

ENGN stock →

enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 81 employees

About Sutro Biopharma

STRO stock →

Sutro Biopharma, Inc. operates as an oncology company.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 129 employees

ENGN vs STRO FAQ

Which is bigger, enGene Therapeutics or Sutro Biopharma?

Sutro Biopharma (STRO) is larger, with a market capitalization of $142.77M compared with $116.61M for enGene Therapeutics (ENGN).

Which stock has performed better over the past year, ENGN or STRO?

STRO returned +2.38% over the past 12 months, compared with -75.00% for ENGN (price return, excluding dividends). Past performance does not predict future results.

Are enGene Therapeutics and Sutro Biopharma in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons